Diffusion Pharmaceuticals (NASDAQ:DFFN) Upgraded by ValuEngine to Buy

Diffusion Pharmaceuticals (NASDAQ:DFFN) was upgraded by research analysts at ValuEngine from a “hold” rating to a “buy” rating in a report released on Thursday, ValuEngine reports.

Shares of DFFN traded up $0.03 during midday trading on Thursday, hitting $2.29. The company had a trading volume of 27,096 shares, compared to its average volume of 247,696. The firm has a 50 day moving average price of $2.57. The stock has a market cap of $7.64 million, a PE ratio of -0.38 and a beta of -0.02. Diffusion Pharmaceuticals has a 52 week low of $1.83 and a 52 week high of $11.00. The company has a current ratio of 5.35, a quick ratio of 5.35 and a debt-to-equity ratio of 0.02.

Diffusion Pharmaceuticals (NASDAQ:DFFN) last released its earnings results on Thursday, May 9th. The company reported ($0.81) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.90) by $0.09. On average, research analysts predict that Diffusion Pharmaceuticals will post -2.27 EPS for the current fiscal year.

A hedge fund recently bought a new stake in Diffusion Pharmaceuticals stock. Two Sigma Investments LP purchased a new stake in Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) in the 4th quarter, according to its most recent disclosure with the SEC. The fund purchased 32,176 shares of the company’s stock, valued at approximately $64,000. Two Sigma Investments LP owned 0.95% of Diffusion Pharmaceuticals as of its most recent filing with the SEC. Institutional investors own 6.20% of the company’s stock.

Diffusion Pharmaceuticals Company Profile

Diffusion Pharmaceuticals Inc, a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of pancreatic cancer and metastatic brain cancer; and Phase II trial for the treatment of acute stroke.

Featured Article: Day Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.